In Brief: Theratech/SmithKline Beecham's TheraDerm
Executive Summary
Theratech/SmithKline Beecham's TheraDerm: FDA has completed pre-approval inspection of $17 mil. commercial scale manufacturing facility for testosterone patch, Theratech CEO Dinesh Patel tells Dillon, Read analysts conference May 11 in New York City. In addition, the company predicts an NDA filing in second half of 1995 for estradiol patch, licensed to Proctor & Gamble worldwide except for Japan...